1
3
4
News & Events
FDA Updates for the Week of July 17, 2023
July 22, 2023
The FDA has cleared several new products this week. Read more
Allecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP®
June 27, 2023
Cefepime/enmetazobactam is a 4th generation antibiotic for the treatment of complicated urinary tract infections. Read more
Test Based on Glycoproteomic Profiles Shows High Sensitivity for Advanced Adenomas
June 27, 2023
InterVenn Biosciences reported their serum profiles can accurately detect advanced adenomas. Read more
6
7
News & Events
FDA Updates for the Week of July 17, 2023
July 22, 2023
The FDA has cleared several new products this week. Read more
Allecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP®
June 27, 2023
Cefepime/enmetazobactam is a 4th generation antibiotic for the treatment of complicated urinary tract infections. Read more
Test Based on Glycoproteomic Profiles Shows High Sensitivity for Advanced Adenomas
June 27, 2023
InterVenn Biosciences reported their serum profiles can accurately detect advanced adenomas. Read more
14
Championing
collaborations
that improve health
and the quality of life
for everyone.

#JoinForces
#LifeSciencesInTheFuture
21
25
29
35
37
News & Events
FDA Updates for the Week of July 17, 2023
July 22, 2023
The FDA has cleared several new products this week. Read more
Allecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP®
June 27, 2023
Cefepime/enmetazobactam is a 4th generation antibiotic for the treatment of complicated urinary tract infections. Read more
Test Based on Glycoproteomic Profiles Shows High Sensitivity for Advanced Adenomas
June 27, 2023
InterVenn Biosciences reported their serum profiles can accurately detect advanced adenomas. Read more
39
41